Vertex Pharmaceuticals: The Stock Hasn't Dropped Enough Yet

When I last wrote about the biotech stock Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) a month ago, its price had declined by ~20%. This is exactly the extent of correction I had forecast for it, but with a difference. I had expected the decline toManika is a macroeconomist with over 20 years of experience in industries including investment management, stock broking, investment banking. She also runs the profile Long Term Tips [LTT], which focuses on the generational opportunity in the green economy. ...